A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to new data.
from Top Health News -- ScienceDaily https://ift.tt/2QmSzBG
via IFTTT
No comments:
Post a Comment